血栓模块素耐药性作为COVID-19中的新型前血栓性途径
Ana Marco-Rico1,2,3, Adrián Montaño4, Francisco López-Jaime4
1Thrombosis and Hemostasis Department, Hematology Service, University General Hospital, Dr. Balmis Alicante, Avenida Pintor Baeza 12, Alicante, 03010, Spain. marco_anaric@gva.es.
Scientific reports
|August 12, 2025
概括
患有血栓模块素 (TM) 耐药性的COVID-19患者,通过较低的内源性血栓潜力 (ETP) 抑制来表示,面临严重临床事件的更高风险. 血生成测试可以预测住院COVID-19患者的不良预后.
科学领域:
- 医学研究 医学研究
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
背景情况:
- COVID-19与高凝血性和内皮功能障碍有关.
- 在严重的COVID-19中释放的angiopoietin 2可能会降低循环中的血栓模块素 (TM),这是血栓生成的关键调节剂.
- 现有的关于COVID-19中TM耐药性的数据需要进一步的强有力的验证.
研究的目的:
- 为了评估住院COVID-19患者的血栓模块素 (TM) 耐药性.
- 评估TM耐药性与严重临床事件 (SCE) 的发展之间的相关性.
- 调查TM耐药性对COVID-19患者结果的预测价值.
主要方法:
- 使用血栓生成试验 (TGT) 来测量内源性血栓潜力 (ETP) 抑制.
- 包括47名住院的COVID-19患者.
- 与SCE和凝块硬性的发生相关的ETP抑制百分比.
主要成果:
- 54.8%的患者表现出TM耐药性 (ETP抑制<40%).
- 与没有SCE患者 (47.6%,p=0.019) 相比,SCE患者的ETP抑制显著降低 (24.3%).
- 较低的ETP抑制与凝块刚度增加相关 (r=-0.372,p=0.0167) 并是SCE (AUC=0.803) 的强有力的预测因子.
结论:
- 血生成测试是住院COVID-19患者风险分层的一个有价值的工具.
- 增加的TM抵抗,以较低的ETP抑制为标志,与SCE发展密切相关.
- TM抗性显示出作为预测COVID-19中预后不佳的独立标记物的潜力.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
903
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22